Cytokinetics (CYTK) said Tuesday it is enrolling patients in a phase 3 trial designed to evaluate the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
The trial is expected to randomize about 1,800 patients on a 1:1 basis to receive omecamtiv mecarbil or placebo, the company said.
Cytokinetics is conducting the trial in collaboration with the Duke Clinical Research Institute.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。